By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Correlogic Systems this week said that it has fulfilled European Union regulatory requirements to CE Mark its OvaCheck test for epithelial ovarian cancer. The test is a multiplex assay that measures the relative ratios of eight proteins. The Germantwon, Md.-based firm said that it is currently in discussions with potential partners for distribution of OvaCheck in Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.